Telcagepant failure is a headache for Merck (and perhaps Pfizer) but a break for others
This article was originally published in Scrip
Executive Summary
While Merck’s latest job cuts were at the fore of its Q2 update (scripintelligence.com, 1 August 2011), the discontinuation of its promising Phase III acute migraine therapy telcagepant is also notable and will add to the company’s woes. It had been expected to become an important treatment option for migraineurs and compete with the triptan class, the standard of care for the past 20 years. Without telcagepant, the acute migraine market will contract, leaving the prophylactic treatment of migraine as the biggest opportunity for developers.
You may also be interested in...
Biohaven’s Nurtec May Be First Migraine Drug For Acute Treatment And Prevention
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
Migraine Drug Atogepant Delivers Good News When Allergan Needs It Most
Oral CGRP inhibitor atogepant delivers strong Phase IIb/III results in episodic migraine prevention less than a week after activist investors went public with their push for a management shakeup to reverse Allergan's falling stock price.
Biohaven Posts Positive Migraine Results, But Investors Are Wary
Biohaven's stock price fell significantly after it reported positive Phase III results for rimegepant in the acute treatment of migraine, but concerns about differences between the company's Phase II and III data eased as potential benefits over Allergan's competing oral CGRP inhibitor emerged.